An article from April reported about the publication of inspection results by the British MHRA for 2016. Amongst other things, this publication addresses deficiencies concerning validation/qualification.
Revised USP general chapters <660> and <1660> have been published for comment in the Pharmacopeial Forum. Read more about the drafts for Containers-Glass and Evaluation of the Inner Surface Durability of Glass Containers.
During an FDA inspection at the Kansas-based company Hospira in mid 2016, the FDA encountered several GMP violations which resulted in a Warning Letter. The GMP deficiencies concerning visual inspection as well as the handling of distributed batches which were contaminated with particles even lead to the assertion that the company's process of manufacturing injectable products was out of control.
In the course of an FDA inspection at a Brazilian manufacturer of antibiotics, the inspector observed a few serious GMP violations which led ultimately to a Warning Letter. Read more about the FDA Warning Letter issued to the company Antibioticos Do Brasil Ltda.
On 12 April the European Medicines Agency (EMA) has released a draft guideline on good clinical practice (GCP) compliance in relation to Trial Master Files (TMF) for public consultation. The guideline is part of the work related to the implementation of the new Clinical Trial Regulation (EU) 536/2014. It also contains the revised version of the reflection paper on TMF, considering comments collected during public consultation. Read more about the Guideline on GCP compliance in relation to trial master file (paper and/or electronic) for content, management, archiving, audit and inspection of clinical trials.
In April 2017 the European Medicines Agency (EMA) published the final report of its joint pilot programme with the United States (US) Food and Drug Administration (FDA) for the parallel assessment of sections of applications relevant to quality by design (QbD). Read more about the final Report from the EMA-FDA QbD pilot program.
Nitrogen often comes in contact with a product during manufacturing and is therefore relevant for its quality, especially when it comes to the manufacture of sterile products. Nonetheless, the use of nitrogen is significantly less specified than that of pharmaceutical water. Parameters and limits for nitrogen have to be defined by the pharmaceutical users themselves.
In January 2017, Sato Yakuhin Kogyo Co. Ltd., a pharmaceutical company in Japan, received a Warning Letter from the FDA. During the FDA inspection, incomplete data were criticized in the HPLC and UV analysis. Find out more about the FDA Warning Letter issued to Sato Yakuhin Kogyo.
On 17 March 2017 the European Medicines Agency (EMA) released a new policy on the handling of information which has been received from external sources about serious concerns, e.g. related to GMP deviations or Data Integrity issues. Please read more about the EMA policy.
In many cases, gaseous media used such as compressed air contact the product and are thus, by definition, quality relevant, and in particular, of course, in the case of sterile products. However, compared to e.g. the liquid medium pharmaceutical water, they are much less explicitly specified. Pharmaceutical users have to define their requirements for compressed air themselves.
The USP proposes two new general chapters <665> and <1665> to address the qualification of polymeric components used in the manufacture of pharmaceutical and biopharmaceutical APIs and drug products. Chapter <665> was previously published as Plastic Components and Systems Used in Pharmaceutical Manufacturing <661.3>. Read more about the proposals for Polymeric Components and Systems Used in the Manufacturing of Pharmaceutical and Biopharmaceutical Drug Products and Plastic Components and Systems Used to Manufacture Pharmaceutical Drug Products.
The website of the US Pharmacopoeia (USP) comprises a document with frequently asked questions and answers on the subject of pharmaceutical water. The not very well known page contains some very interesting points.
At the beginning of March 2017, Lumis, an API manufacturer in China, received a Warning Letter from the the US FDA. During the FDA inspection the certificates of analysis (COAs) were criticized. The issued certificates did not contain all relevant information on the quality that would have been necessary for the customer. Learn more about the FDA Warning Letter issued to Lumis.
The EDQM has recently published a list of the top 10 deficiencies found in CEP applications.Find out how to avoid undesired inquiries from the EDQM on impurities in starting materials, elemental impurities and residual solvents in the framework of an application procedure.
To ascertain the information required by QPs to allow release of medicinal products impacted by a statement of non-compliance, the European QP Association (EQPA) performed a survey among its members. This survey on the certification of batches with GMP issues generated some interesting results.
In Pharmeuropa 29.2 several drafts of general chapters regarding packaging components and materials made of PVC have been published for comment. Read more about the drafts on materials and containers based on plasticised poly(vinyl chloride).
Reverse osmosis as a main barrier to all types of impurities plays an essential role in both the production of Purified Water (PW) and cold WFI production. In the pharmaceutical industry, this module has to be heat sanitisable. Now the question is how often heat sanitisation has to be performed?